KTHERA’s innovative chemistry falls directly into the empty sweet spot between opioids, NSAIDs, and acetaminophen, avoiding addictive potential, GI and kidney issues, and liver toxicity. We have over 100 promising analgesic compounds, many with potency exceeding morphine, oral bioavailability, optimal half life, no activity at opioid receptors, validated in multiple animal models and human trials.